Deciphera Pharmaceuticals

Deciphera Pharmaceuticals DSCR

Delisted·Jun 10, 2024

The Debt Service Coverage Ratio (DSCR) of Deciphera Pharmaceuticals (DCPH) as of Oct 31, 2026 is -67.07. In the previous year, Debt Service Coverage Ratio (DSCR) was -24.78 — a change of 170.62% (lower).

DSCR

-67.07

YoY

170.62%

Last updated:

Debt Service Coverage Ratio (DSCR) of Deciphera Pharmaceuticals is 2018 -67.07 . Debt Service Coverage Ratio (DSCR) of Deciphera Pharmaceuticals was 2017 -24.78 . It decreases by 170.62% lower compared to the previous year.

The Deciphera Pharmaceuticals DSCR history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

DSCR
Date
DSCR
Jan 1, 2015
-7.11 USD
Jan 1, 2016
-13.84 USD
Jan 1, 2017
-24.78 USD
Jan 1, 2018
-67.07 USD
The Deciphera Pharmaceuticals DSCR history
YEARDSCRYoY
-67.07+170.62%
-24.78+79.02%
-13.84+94.67%
-7.11—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Deciphera Pharmaceuticals Stock analysis

What does Deciphera Pharmaceuticals do? Deciphera Pharmaceuticals Inc is a US biopharmaceutical company specializing in the research, development, and marketing of innovative therapeutic solutions for cancer patients. The company was founded in 2003 and is headquartered in Waltham, Massachusetts. Deciphera follows a diversified business model based on multiple pillars. On one hand, the company conducts its own research and development activities to develop new therapy approaches for cancer patients. Deciphera focuses on the research of kinase inhibitors, which offer promising approaches in cancer therapy. On the other hand, the company pursues a licensing strategy by acquiring and further developing already developed active ingredients for cancer therapies in order to make them available to patients. For this purpose, the company collaborates with various partner companies and leading academics and experts in the field of cancer therapy. Deciphera is also engaged in international collaboration through partnerships with local partners in Asia for the research of new cancer therapy approaches. The company invests significant efforts in research and development to constantly adapt its products to the latest scientific advances. Deciphera aims to develop effective and safe therapies for cancer patients that improve their quality of life and increase their chances of survival. The company relies on the research of kinase inhibitors that specifically target certain signaling pathways in cancer cells and thereby inhibit the growth of tumor cells. The company already has a number of products in clinical trials and approval processes that show promising results and are expected to be on the market soon. One promising drug is Ripretinib, dedicated to the cancer type GIST. The goal is to offer a range of cancer medications that have significant treatment success and offer customers high chances of success. Overall, Deciphera Pharmaceuticals is a dynamic and research-oriented company that utilizes the most innovative technologies to give hope to cancer patients and improve the treatment of cancer diseases. With its broad portfolio of active ingredients and therapy approaches, its international presence, and its dedicated research and development, Deciphera Pharmaceuticals Inc. is at the forefront when it comes to innovative cancer treatment therapies. Deciphera Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Deciphera Pharmaceuticals stock

Debt Service Coverage Ratio (DSCR) of Deciphera Pharmaceuticals is -67.07 in 2018.

Debt Service Coverage Ratio (DSCR) of Deciphera Pharmaceuticals changed from -24.78 to -67.07, representing a 170.62% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Service Coverage Ratio (DSCR) Deciphera Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

The DSCR measures a company's ability to service its debt obligations from operating income. A ratio above 1.0 indicates sufficient income to cover debt payments.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt Service Coverage Ratio (DSCR)'s Deciphera Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Deciphera Pharmaceuticals

All Key Metrics — Deciphera Pharmaceuticals